# Post Transplant Donor Lymphocyte Infusion

> **NCT00167180** · PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 57 (actual)

## Conditions studied

- Leukemia, Myeloid, Chronic
- Lymphomas
- Multiple Myeloma
- Myelodysplastic Syndrome
- Leukemia, Lymphocytic, Acute
- Leukemia, Lymphocytic, Chronic
- AML

## Interventions

- **PROCEDURE:** Donor Lymphocyte Infusion
- **DRUG:** Induction Chemotherapy

## Key facts

- **NCT ID:** NCT00167180
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** 2017-11-21
- **Final completion:** 2018-12-24
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Accrual Goal Met
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00167180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00167180, "Post Transplant Donor Lymphocyte Infusion". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00167180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*